Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Recruiting now
Conditions studied: Migraine, Episodic Migraine, Chronic Migraine, Headache
In brief
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Key facts
- Study ID
- NCT07159750
- Run by
- Hospital Universitari Vall d'Hebron Research Institute
- People needed
- 700
- Starts
- 2024-01-02
- Expected to finish
- 2026-01-01
- Last updated by the study team
- 2025-09-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Migraine diagnosis according to ICHD-III.
- Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
- Signature of informed consent.
You may not qualify if…
- Presence of headache different from migraine.
- Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
Where it is running
- Mersin University — Mersin, Turkey (Türkiye) (enrolling)
- FLENI — Buenos Aires, Argentina (enrolling)
- Pontificia Universidad Católica de Chile — Santiago, Chile (enrolling)
- Neuromedica — Medellín, Colombia (enrolling)
- Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno — Rovinj, Croatia (enrolling)
- Charité Universitätsmedizin Berlin — Berlin, Germany (enrolling)
- LMU University Hospital — München, Germany (enrolling)
- University of L'Aquila — L’Aquila, Italy (enrolling)
- University of Modena and Reggio Emilia — Modena, Italy (enrolling)
- National Neurological Institute C. Mondino Foundation — Pavia, Italy (enrolling)
- IRCCS San Raffaele — Roma, Italy (enrolling)
- Universiti Putra Malaysia — Serdang, Selangor, Malaysia (enrolling)
- Neuroclinic Norway — Lillestrøm, Norway (enrolling)
- Wrocław Medical University — Wroclaw, Poland (enrolling)
- Hospital Santa Maria Lisbon — Lisbon, Portugal (enrolling)
- Germans Trias i Pujol Hospital — Badalona, Barcelona, Spain (enrolling)
- Vall d'Hebron University Hospital — Barcelona, Barcelona, Spain (enrolling)
- Hospital Universitari de Bellvitge — L'Hospitalet de Llobregat, Barcelona, Spain (enrolling)
- University of Miami, Miller School of Medicine — Miami, Florida, United States (enrolling)
- Hospital de Viladecans — Viladecans, Barcelona, Spain (enrolling)
- Hospital General Universitario de Albacete — Albacete, Spain (enrolling)
- Fundación Jiménez Díaz — Madrid, Spain (enrolling)
- Hospital Universitario Gregorio Marañón — Madrid, Spain (enrolling)
- La Paz University Hospital — Madrid, Spain (enrolling)
- Hospital Clínico Universitario Lozano Blesa — Zaragoza, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.